Revenue segments as reported by the company.

Net product sales

Collaboration revenue

Other revenue

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Other operating (income) expense, net

Acquired in-process research and development

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: EYLEA, Dupixent, Praluent, Kevzara, Libtayo, ARCALYST, and ZALTRAP. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically-humanized mice to produce optimized fully-human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Regeneron reports robust Q4 earnings, eyes strategic launches and collaborations

Regeneron Pharmaceuticals showcased strong financial performance and pipeline advancements in Q4 2022.
The company's focus on safety, efficacy, and strategic imperatives positions it for future growth.
Challenges include competitive positioning, trial data anticipation, and managing uncertainties.
Opportunities in market launches, accelerated approvals, and innovative collaborations drive future potential.

Regeneron excels in Q1 with strong revenue growth and pipeline advancements

Regeneron Pharmaceuticals delivered a strong performance in Q1 2023, driven by revenue growth and pipeline advancements in key therapeutic areas like DUPIXENT and EYLEA.
Despite operational challenges in market positioning and regulatory considerations, the company's strengths in research capabilities and strategic planning present growth opportunities.
With a focus on commercialization efforts, expanding indications, and leveraging genetic insights, Regeneron is poised to capitalize on opportunities for sustained success and innovation.
Navigating challenges in market competition and regulatory uncertainties, Regeneron remains proactive in addressing key issues to maintain its position as a leading biopharmaceutical company.

Regeneron reports strong Q2 earnings, eyes aflibercept launch

Regeneron Pharmaceuticals demonstrated strong financial performance and commercial success in Q2 2023.
While facing regulatory challenges, the company remains optimistic about pipeline advancements and potential launches.
Balancing efficacy and safety in treatments, Regeneron aims to capitalize on growth opportunities and strategic partnerships.
Robust cash position and focus on patient well-being position Regeneron for continued success and market expansion.

Regeneron posts robust Q3 results, eyes innovation and market growth

Regeneron's Q3 performance reflects strong revenue growth, financial stability, and promising market potential for key products like Dupixent and EYLEA HD.
While facing legal challenges and competitive pressures, the company's strategic focus on innovation, R&D, and shareholder value management positions it for long-term success.
With a robust pipeline, unique therapeutic targets, and a solid financial foundation, Regeneron is poised for continued growth, market leadership, and innovation in the biopharmaceutical industry.

Regeneron posts strong Q4 results, eyes growth through innovation

Regeneron Pharmaceuticals delivered a strong performance in Q4 2023, driven by successful product launches and financial results in line with expectations.
The company's focus on innovation, strategic leadership, and capital allocation priorities position them well for future growth and market success.
While facing challenges in market dynamics and competition, Regeneron has opportunities to leverage new product approvals and innovative treatment approaches.
Overall, Regeneron's performance highlights their resilience, strategic vision, and commitment to advancing healthcare through groundbreaking therapies.

Regeneron posts solid Q1 results, faces FDA request challenges

Regeneron Pharmaceuticals delivered strong financial performance in Q1 2024, driven by Dupixent and EYLEA HD.
The company's robust pipeline and focus on innovation position it well for future growth.
Challenges include FDA requests for Dupixent efficacy analyses and market entry hurdles for new products.
Opportunities lie in advancing therapies for COPD, severe food allergies, and expanding cancer treatment options.

Regeneron posts robust Q2 earnings, eyes pipeline expansion opportunities

Regeneron Pharmaceuticals demonstrated strong financial performance and product sales growth in Q2.
While facing regulatory challenges, the company's pipeline and market position remain robust.
Opportunities for expansion and innovation present avenues for future growth.
Overall, Regeneron's Q2 results reflect resilience and strategic focus.

Regeneron Pharmaceuticals reports strong Q3 results and eyes innovative growth

Regeneron's Q3 performance reflects solid revenue and earnings growth driven by key products. While facing regulatory challenges and capital allocation decisions, the company's focus on innovation and strategic investments positions it well for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. The firm accelerates the traditional drug development process through its proprietary VelociSuite technologies such as VelocImmune, which uses unique genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies. The company was founded by Alferd G. Gilman, Leonard S. Schleifer, George Damis Yancopoulos, and Eric M. Shooter on January 8, 1988, and is headquartered in Tarrytown, NY.

TARRYTOWN, N.Y., April 6, 2021 /PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2021 financial and operating results on Thursday, May 6, 2021, before the U.S. financial markets open.

Regeneron to Report First Quarter 2021 Financial and Operating Results and Host Conference Call and Webcast on May 6, 2021

Cisco Systems

Dollar Tree

DocuSign

Intel

Microsoft

Investors need to hold the best companies that money can buy on the Nasdaq, amid a growing weakness in the technology stock index. The post 7 Best Stocks on the Nasdaq appeared first on InvestorPlace.

7 Best Stocks on the Nasdaq

Pinterest

PayPal

Their growth prospects are too good to ignore.

3 Stocks Cathie Wood Is Selling That Long-Term Investors Should Be Buying

There are a couple of obstacles that could get in the way.

Could Regeneron's Antibody Therapy Be as Important as Vaccines in Fighting COVID?

TARRYTOWN, N.Y., March 30, 2021 /PRNewswire/ -- Protocol W trial data confirm results from PANORAMA trial showing EYLEA significantly reduced vision-threatening complications and improved anatomic measures of diabetic retinopathy    Although patients' overall vision was similar in the EYLEA and sham groups at two years in Protocol W, a new analysis from PANORAMA shows that delaying EYLEA treatment (sham group) was associated with prolonged periods of vision loss Two diabetic retinopathy trials (Protocol W and PANORAMA) have now shown the benefit of EYLEA every 16 weeks following an initial dosing period; Regeneron to discuss 16-week dosing interval with U.S. FDA Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced JAMA Ophthalmology has published initial results from the National Institutes of Health-sponsored Protocol W trial assessing EYLEA® (aflibercept) Injection in patients with moderate to severe non-proliferative diabetic retinopathy (NPDR), without center-involved diabetic macular edema (CI-DME).

NIH-sponsored Trial Finds EYLEA® (aflibercept) Injection Reduced Vision-threatening Complications by 68% after Two Years in Diabetic Retinopathy Patients

Regeneron (REGN) announces positive data from a phase III study on its antibody cocktail for COVID-19.

Regeneron (REGN) Announces Positive Data on COVID-19 Cocktail

Positive results from Regeneron Pharmaceuticals' Phase 3 trial of its Covid-19 antibody could mean far higher sales of the therapy this year than analysts had previously expected.

Regeneron's Covid-19 Antibody Could See Substantially Higher Sales This Year. Here's Why.

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) said Tuesday that a lower dose of its treatment for COVID-19 reduced hospitalization and death rates. This is "good news that could be really big news," Regeneron President George Yancopoulos said on CNBC's "Squawk Box.

Regeneron's President On COVID-19 Antibody Cocktail: 'Good News That Could Be Really Big News'

Shares of Regeneron Pharmaceuticals Inc. gained 1.1% in premarket trading on Tuesday after the drug maker said its COVID-19 antibody cocktail still reduced the risk of hospitalization and death by about 70% among COVID-19 patients at high risk of hospitalization when prescribed a lower dose. The drug, REGEN-COV, first received emergency authorization in November as a 2,400 milligram dose administered intravenously; the new data examines a 1,200 milligram dose and found that the lower dosing regimen had comparable clinical results.

Regeneron says its COVID-19 treatment still works even at a lower dose

Regeneron Pharmaceuticals Inc (NASDAQ: REGN) has announced that even a lower-than-authorized dose of its combination of monoclonal antibody (mAbs) reduced hospitalization or death by 70% in non-hospitalized COVID-19 patients. The company seeks emergency use approval for the lower dose.

Regeneron's Lower Dose Of COVID-19 Antibody Cocktail Cuts Hospitalization, Death By 70%

TARRYTOWN, N.Y., March 23, 2021 /PRNewswire/ --  REGEN-COV also significantly shortened the duration of symptoms by 4 days All doses (8,000 mg, 2,400 mg and 1,200 mg) had similar efficacy across all endpoints Companion dose-ranging Phase 2 trial showed significant and comparable viral reductions for all REGEN-COV doses tested, including as low as 300 mg FDA recently updated U.S. EUA fact sheets for all authorized monoclonal antibody treatments, indicating that REGEN-COV is the only one to retain potency against key emerging variants Regeneron will share new data with regulatory authorities immediately and request that a lower 1,200 mg dose be added to EUA Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced positive topline results from the largest trial to date assessing a COVID-19 treatment in infected non-hospitalized patients (n=4,567).

Phase 3 Trial Shows REGEN-COV™ (casirivimab with imdevimab) Antibody Cocktail Reduced Hospitalization or Death by 70% in Non-hospitalized COVID-19 Patients

Biogen

Pfizer

They're making headway into tomorrow's hot markets.

Got $5,000? Consider These 3 Leading Pharma Stocks

Eli Lilly

The FDA updated its fact sheets on the monoclonal antibody (mAb) treatments for COVID-19 from Eli Lilly And Co (NYSE: LLY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN), highlighting additional data on the vulnerability of the emerging COVID-19 variants to each of the mAb therapies. “Some variants can cause resistance to one or more of the mAb therapies authorized to treat COVID-19,” FDA said.

FDA Updates Fact Sheets For Eli Lilly, Regeneron's COVID-19 Antibody Therapies Under Emergency Use

Regeneron Pharmaceuticals, Inc. (REGN) Presents at Oppenheimer Healthcare Broker Conference Call - (Transcript)

Sanofi

Regeneron (REGN) and partner Sanofi announce favorable data on their oncology drug Libtayo from a phase III study on cervical cancer.

Regeneron (REGN), Sanofi's Libtayo Positive for Cervical Cancer

Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) revealed that they're stopping a Phase 3 cervical cancer trial early after Libtayo showed cutting the risk of death by 31% over chemotherapy. The Independent data monitoring committee unanimously recommended stopping the trial after reviewing the OS data at an interim analysis, thus paving the way for regulatory approval this year.

Regeneron/Sanofi Boast Positive Overall Survival Results In Late-Stage Cervical Cancer Study

TARRYTOWN, N.Y. and PARIS, March 15, 2021 /PRNewswire/ -- Libtayo is the first immunotherapy to demonstrate improved overall survival in patients with cervical cancer, reducing the risk of death by 31% compared to chemotherapy Trial enrolled patients with advanced cervical cancer regardless of PD-L1 status Fourth cancer type where Libtayo has positive pivotal data; first-in-class survival results in cervical cancer follow first-in-class pivotal results in advanced BCC and advanced CSCC Regulatory submissions planned in 2021 Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Sanofi today announced positive results demonstrating an overall survival (OS) benefit from the Phase 3 trial investigating the PD-1 inhibitor Libtayo® (cemiplimab) monotherapy compared to chemotherapy, in patients previously treated with chemotherapy whose cervical cancer is recurrent or metastatic.

Phase 3 Trial of Libtayo® (cemiplimab) Monotherapy in Advanced Cervical Cancer Stopped Early for Positive Result on Overall Survival

A few months back in December 2020, we discussed why Regeneron stock looks undervalued. The stock since then has had a volatile ride with gains of 7% between early December 2020 and late January 2021, followed by a drop of 15% to $468 currently.

Regeneron Stock Set To See Much Higher Levels

HUYA Inc - ADR

Nintendo

Teladoc

LendingTree

Twilio

Zoom Video

The anti-Wolf of Wall Street, Cathie Wood brings honesty and integrity to the world of high finance. Her strong track record confirms that nice folks can finish first.

7 Stocks That Cathie Wood Likes and You Should Too

Regeneron Pharmaceuticals, Inc. (REGN) Management Presents at Barclays Global Healthcare Conference (Transcript)

Future growth will depend on its new checkpoint inhibitor wrangling market share away from Merck's Keytruda.

Beyond COVID, Regeneron Is Betting Big on Oncology

AbbVie

Bristol-Myers

Novavax

Vertex Pharmaceuticals

The biotech industry seems poised for further growth due to factors like advancements in drug research and faster regulatory process, making it wise to look at names like AbbVie (ABBV) and Novavax (NVAX)

5 Stocks to Watch Amid Continued Expansion in the Biotech Industry

Regeneron (REGN) reported earnings 30 days ago. What's next for the stock?

Regeneron (REGN) Down 7.5% Since Last Earnings Report: Can It Rebound?

The FDA has accepted for review the supplemental marketing application seeking approval for Dupixent (dupilumab). It is an add-on treatment for children aged 6 to 11 years with uncontrolled moderate-to-severe asthma, jointly developed by Sanofi SA (NASDAQ: SNY) and Regeneron Pharmaceuticals Inc (NASDAQ: REGN) under a global collaboration agreement.

Sanofi/Regneron's Dupixent Application For Asthma In Children Accepted For FDA Review

FDA accepts Dupixent® (dupilumab) for review in children with moderate-to-severe asthma

News for Regeneron Pharmaceuticals Stock (REGN)